At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
Sep 23, 2015
- Results to be Presented September 29th at 2015 European Respiratory Society Congress -
Pulmatrix, Inc. (NASDAQ: PULM) will report data from a Phase 1B study evaluating PUR0200, an iSPERSE formulation of a long acting muscarinic antagonist (LAMA) bronchodilator, on September 29th at...
Sep 11, 2015
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease, today announced that preclinical data...
Sep 3, 2015
Pulmatrix, Inc., (NASDAQ: PULM) will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10, 2015 at 11:40 am EDT. As part of the presentation, Robert...
Sep 2, 2015
Pulmatrix, Inc. (NASDAQ: PULM) has been granted U.S. patent 9,119,778, for the Company's underlying iSPERSE™ inhaled dry powder technology. The patent broadly covers small, dense and dispersible...
Aug 14, 2015
Pulmatrix, Inc., (NASDAQ: PULM) reports second quarter financial results and provides an update on the progress year to date on the business and its drug development pipeline. "During the second...